T2D Talks | GPnotebook Resources

This promotional website has been developed and funded by Boehringer Ingelheim.
The media partners for this activity are GPnotebook and Diabetes on the net. GPnotebook and Diabetes on the net have had no input into the content of this website.

Prescribing information for the United Kingdom and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

About.

Welcome to the T2D Talks Hub, an educational platform designed to equip HCPs with resources supporting the management of people living with T2D.

What this hub provides

This hub offers insightful resources in a range of formats:

Discover educational video-based content and practical, downloadable leaflets on key areas in T2D, to support your clinical practice.
Explore downloadable leaflets designed for patients to further their knowledge and support engagement with their diabetes-related health.

The evolving landscape:
Type 2 diabetes management and diabetes-related mental health

Professor Richard Holt & Nicola Milne

Check out our latest on-demand videos on managing T2D and diabetes-related mental health

Download an educational one-page leaflet designed to support HCPs addressing treatment non-adherence in the management of adults living with T2D.

Access patient leaflets, designed to support and educate adults living with T2D.

Focus on: T2D and CKD

Did you know?

Approximately 45,000 premature deaths in the UK every year are due to CKD¹

Experts are urging for more to be done to:

Help patients recognise the signs of CKD and engage with CKD testing²
Support HCPs with the early detection of CKD and identifying opportunities for intervention³

Why is UACR testing important in diabetes?

UACR testing is an early indicator of kidney damage⁴; however, the most recent National Diabetes Audit shows that almost 31% of people with T2D in England did not have a urinary microalbumin test in the past year.⁵ One reason why UACR testing rates are low is because patients do not provide urine samples when requested.⁶ There is therefore an urgent need to improve rates of UACR testing in people at risk of, or living with CKD.⁷

Resources.

Patient leaflet

What has diabetes got to do with my kidneys?

Download a leaflet for your patients which outlines the purpose of kidney screenings and the importance of returning urine samples. This leaflet was made in collaboration with Sanjay Mistry, an expert through experience who himself was living with diabetes, using patient-friendly language.

HCP leaflet

What’s best practice for managing T2D in people living with complex comorbidities?

Download a one-page leaflet that highlights a case-based approach to managing T2D in adults with complex comorbidities, reflecting on key considerations and learnings from fictional patient case snapshots.

CKD: chronic kidney disease; CVD: cardiovascular disease; HCP: healthcare professional; T2D: type 2 diabetes; UACR: urine albumin-creatinine ratio.

Please review the Summary of Product Characteristics for Linagliptin for the full information on dosing, adverse events, contraindications, special warnings and precautions for use before prescribing. Available at: www.medicines.org.uk (UK) and https://www.medicines.ie (ROI).⁸

References

Kidney Care UK (2026). Key facts about kidneys. Available at: https://kidneycareuk.org/kidney-disease-information/about-kidney-health/facts-about-kidneys/ (accessed May 2026)
Kidney Care UK (2023). Let’s talk kidneys. Opportunities for early intervention in chronic kidney disease. Available at: https://kcuk.cdn.ngo/media/documents/Kidney_Care_UK_-_CKD_Lets_talk_kidneys_report_-_Hyperlinks.pdf (accessed May 2026)
Kidney Research UK (2024). Chronic kidney disease and prevention: Harnessing the potential of early intervention and disease management. Available at: https://www.kidneyresearchuk.org/wp-content/uploads/2023/03/Kidney-Research-report-on-prevention-and-early-detection.pdf (accessed May 2026)
Christofides EA and Desai N. J Prim Care Community Health 2021;12:21501327211003683

NHS England (2025). National Diabetes Audit Core Report 1: Care Processes and Treatment Targets 2024–25 Underlying data. Available at: https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1-cp-and-tt-data-release-2024-25/nda-report-1-cp-and-tt-data-release-2024-25 (accessed May 2026)
Kidney Research UK (2020). Type 2 diabetics are missing out on an annual kidney test. Available at: https://www.kidneyresearchuk.org/2020/02/20/type-2-diabetics-are-missing-out-on-an-annual-kidney-test/ (accessed May 2026)
UK Kidney Association (2024). Measurement of kidney function. Available at: https://www.ukkidney.org/health-professionals/information-resources/uk-eckd-guide/measurement-kidney-function (accessed May 2026)
Linagliptin Summary of Product Characteristics. Available at: https://www.medicines.org.uk (UK) and https://www.medicines.ie (ROI).

Prescribing information for the United Kingdom and the Republic of Ireland.

Linagliptin is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as⁸:

• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

This promotional website has been developed and funded by Boehringer Ingelheim.
Editorial support for this website has been provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), or by email: [email protected]

PC-GB-112303 | May 2026